Literature DB >> 8888048

Prognostic clues and outcome of early treatment of nonketotic hyperglycinemia.

A Boneh1, Y Degani, M Harari.   

Abstract

Nonketotic hyperglycinemia presenting in the neonatal period is considered a devastating neurological condition. Most patients die soon after birth, and those who survive manifest severe neurological deficits, psychomotor retardation, and convulsions that are difficult to control. These abnormalities probably result from overstimulation of the N-methyl-D-aspartate receptor in the brain. In the present study, we wished to delineate prognostic clues for patients with neonatal (classic) nonketotic hyperglycinemia and to evaluate the results of early treatment with glycine-receptor modulators. The charts of six children treated in our department since 1991 were reviewed for details that might contribute to the prediction of prognosis. Postnatal clinical presentation and initial cerebrospinal fluid and plasma glycine levels were not predictive of outcome, but early treatment with N-methyl-D-aspartate modulators appeared to reduce late neurological complications and probably is as important as treatment with sodium benzoate. Attainment of developmental milestones, however, varies from one patient to another, presumably because of a factor or factors still unknown.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888048     DOI: 10.1016/0887-8994(96)00158-0

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  8 in total

1.  Prediction of long-term outcome in glycine encephalopathy: a clinical survey.

Authors:  Julia B Hennermann; Jeanne-Marie Berger; Ulrike Grieben; Gunter Scharer; Johan L K Van Hove
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

2.  Effect of sodium benzoate in the treatment of atypical nonketotic hyperglycinaemia.

Authors:  J M Neuberger; S Schweitzer; M O Rolland; R Burghard
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  Pulmonary hypertension associated with nonketotic hyperglycinaemia.

Authors:  S Cataltepe; L J van Marter; H Kozakewich; D L Wessel; P J Lee; H L Levy
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

4.  A single nucleotide substitution that abolishes the initiator methionine codon of the GLDC gene is prevalent among patients with glycine encephalopathy in Jerusalem.

Authors:  Avihu Boneh; Stanley H Korman; Kenichi Sato; Junko Kanno; Yoichi Matsubara; Israela Lerer; Ziva Ben-Neriah; Shigeo Kure
Journal:  J Hum Genet       Date:  2005-04-29       Impact factor: 3.172

Review 5.  Nonketotic Hyperglycinemia: Insight into Current Therapies.

Authors:  Magdalena Nowak; Piotr Chuchra; Justyna Paprocka
Journal:  J Clin Med       Date:  2022-05-27       Impact factor: 4.964

6.  One-methyl group metabolism in non-ketotic hyperglycinaemia: mildly elevated cerebrospinal fluid homocysteine levels.

Authors:  J L Van Hove; F Lazeyras; S H Zeisel; T Bottiglieri; K Hyland; H C Charles; L Gray; J Jaeken; S G Kahler
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

7.  Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia.

Authors:  Michael A Swanson; Curtis R Coughlin; Gunter H Scharer; Heather J Szerlong; Kendra J Bjoraker; Elaine B Spector; Geralyn Creadon-Swindell; Vincent Mahieu; Gert Matthijs; Julia B Hennermann; Derek A Applegarth; Jennifer R Toone; Suhong Tong; Kristina Williams; Johan L K Van Hove
Journal:  Ann Neurol       Date:  2015-08-10       Impact factor: 10.422

8.  Nonketotic hyperglycinemia in Suleimaniah Children's Hospital, Riyadh, Saudi Arabia.

Authors:  Devabrata Roy; Ali Al-Asmari; Yousef K Ghazal; Saleh Al-Oqiel
Journal:  Ann Saudi Med       Date:  2004 Sep-Oct       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.